Stay updated with breaking news from Lawrence Eichenfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA has set a PDUFA target action date of July 07, 2024Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United StatessNDA supported by positive efficacy and...
Dr. Eichenfield used this interview segment to respond to the FDA’s recent decision not to approve dupilumab for chronic spontaneous urticaria.
Dr. Eichenfield spoke in this interview segment on the tips shared in his presentation at the Fall Clinical Dermatology conference in Las Vegas.
In this interview, Dr. Eichenfield shared his views on this week’s approval by the FDA of IDP-126 for patients 12 and older with acne.
Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.